Colorectal cancer (CRC) is one of the most common cancers worldwide, posing a serious threat to human health. Metabolic reprogramming represents a critical feature in the process of tumor development and progression, encompassing alterations in sugar metabolism, lipid metabolism, amino acid metabolism, and other pathways. Metabolites hold promise as innovative prognostic biomarkers for cancer patients, which is crucial for targeted follow-up care and interventions. This review aims to provide an overview of the progress in research on metabolic biomarkers for predicting the prognosis of CRC. We also discuss the future trends and challenges in this area.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/metabo14120708 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!